CD274 and non-small cell lung carcinoma: As a biomarker for ICIs treatment, PD-L1 expression level has been used as an auxiliary diagnosis in selecting immunotherapy options for NSCLC patients (11), but it is not suitable to predict the efficacy of immunotherapy in SCLC.